Clinical cancer research : an official journal of the American Association for Cancer Research
Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights.
Allison L Brodsky, Amma Asare, Bryan Fellman, Kristin Anderson, Jun Yao, Sanghoon Lee, Hai Tran, Xun Xu, Jinsong Liu, Joseph Celestino, Richard A Hajek, Margaret B Morgan, Mohammad Mohammad, Pamela Soliman, Aaron Shafer
Published: 202610.1158/1078-0432.CCR-25-1616
Abstract
PURPOSE: Patients with recurrent endometrial or ovarian cancer have poor survival outcomes. We evaluated clinical efficacy and toxicity of copanlisib (a PI3K inhibitor) and niraparib in this patient population with translational insights. PATIENTS AN…
Preview only. Read the full abstract at the source